[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1973

Topical Use of Haloprogin for Candidiasis

Author Affiliations

Birmingham, Ala

Evansville, Ind

Arch Dermatol. 1973;107(5):773. doi:10.1001/archderm.1973.01620200079024

To the Editor.—  Haloprogin (3-iodo-2-propynyl 2,4,5-trichlorophenyl ether) has recently been shown to be topically effective in the treatment of experimental and natural dermatophytic infections.1-4The reported in vitro activity of this antimicrobial against Candida albicans, sometimes at lower concentrations than used against dermatophytes1 suggested that a pilot therapeutic trial of topically applied haloprogin in patients with cutaneous candidiasis could be worthwhile.Ten patients with various types of culturally proven cutaneous candidiasis, several of whom had failed to respond to other current forms of treatment, were selected for this study. Patients were instructed to treat the affected areas twice daily with a cream composed of 1% haloprogin solubilized in polyethylene glycol 400, polyethylene glycol 4,000, diethyl sebacate, and povidone.Excellent response was achieved in all the patients. Eight of the patients suffered from common forms of candidiasis such as intertrigo, balanitis, or perlèche. In these patients the clinical response

First Page Preview View Large
First page PDF preview
First page PDF preview